In early 1990’s during his post-doctoral position at Harvard Medical School, Dr. Kichul Cha, discovered that the results of bioelectrical impedance analysis (BIA) were fundamentally inaccurate. He pointed out how different body parts have different levels of impedance; to accurately analyze body composition, the body would need to be analyzed by segments instead of as a whole. Dr. Cha developed the methods that would overcome the limitations of BIA and transform how BIA would be measured. With this, he created the InBody.
In 1996, Dr. Cha founded InBody Co., Ltd. in Seoul, Korea to produce and promote the InBody and its revolutionary methods. The InBody features Direct Segmental Multi-Frequency Bioelectrical Impedance Analysis and uses an Eight-Point Tactile Electrode Method, which can precisely measure individual body compositions.
In 2000, InBody Co., Ltd. established its first overseas subsidiary in the United States. The InBody and its technology are FDA approved and its results have been validated by research. InBody has also established subsidiaries in Japan and China. InBody has a global network of partners in over 60 countries across North America, Europe, Asia, Middle East, and Africa.